Latest Innovation News

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

FlexiRoam Limited reported an 8.6% revenue decline for FY25 but achieved a remarkable turnaround in the second half, posting positive EBITDA and net profit after a CEO-led operational reset.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.

BlackRock is reshaping its iShares Future Tech Innovators ETF by narrowing its focus to the 30 largest Nasdaq 100 companies and cutting management fees nearly in half, effective October 15, 2025.